The Association for Accessible Medicines has gathered new data to bolster its argument that Medicare Part D plans should place generics on different formulary tiers than higher-priced brand drugs. It cites recent findings that fewer than half of first generics approved by the US Food and Drug Administration since 2016 are commercially available and of these, only about half were included on Part D formularies.
AAM released a white paper, "Access Denied: Why New Generics Are Not Reaching America's Seniors," on 23 September. It...







